公开(公告)号：US11919956B2

公开(公告)日：2024-03-05

申请号：US17321325

申请日：2021-05-14

Applicant: Xencor, Inc.

Inventor： John R. Desjarlais ,  Alex Nisthal ,  Michael Hedvat ,  Matthew Adam Dragovich

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C07K16/30 ,  C07K16/46 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/3069 ,  C07K16/468 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/73

Abstract: Provided herein are novel antigen binding domains and antibodies (e.g., heterodimeric antibodies) that bind Prostate Specific Membrane Antigen (PSMA). In exemplary embodiments, the anti-PSMA antibodies also bind CD3. Such antibodies that bind PSMA and CD3 are useful, for example in the treatment of PSMA-related cancer.

公开(公告)号：US20240059769A1

公开(公告)日：2024-02-22

申请号：US18475358

申请日：2023-09-27

Applicant: Biolojic Design Ltd.

Inventor： ALIK DEMISHTEIN ,  Shmuel BERNSTEIN ,  Tomer SHLAMKOVICH ,  Ayelet CHEN ,  Yehezkel SASSON ,  Marek STRAJBL ,  Itay LEVIN ,  Sharon FISCHMAN ,  Yanay OFRAN ,  Guy NIMROD ,  Alexey SHNYDER ,  Hadar GATTEGNO ,  Nikol MALCHENKO ,  Olga BLUVSHTEIN YERMOLAEV ,  Noam GROSSMAN ,  Liron DANIELPUR ,  Itzhak MEIR ,  Morya IFRACH ,  Reut BARAK FUCHS ,  Michael ZHENIN

IPC: C07K16/24

CPC classification number: C07K16/244 ,  C07K2317/31 ,  C07K2317/732 ,  C07K2317/52 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/33 ,  C07K2317/622

Abstract: Described herein are engineered dual binding antibodies that bind to IL-13 and TSLP and uses thereof. Uses include treating allergic and respiratory conditions. Described herein are also libraries comprising the engineered dual binding antibodies, and methods of producing the engineered dual binding antibodies and functional and biochemical characterization of the antibodies.

公开(公告)号：US11905329B2

公开(公告)日：2024-02-20

申请号：US17834237

申请日：2022-06-07

Applicant: Jounce Therapeutics, Inc.

Inventor： George Robert Mabry, III ,  Stephen Sazinsky

IPC: C07K16/28 ,  A61K39/395 ,  C12N15/64 ,  C12N15/66 ,  C12N5/10 ,  C12N15/00 ,  C07K16/30 ,  A61K39/00 ,  A61P35/00

CPC classification number: C07K16/2818 ,  A61K39/395 ,  A61P35/00 ,  C07K16/30 ,  C12N5/10 ,  C12N15/00 ,  C12N15/64 ,  C12N15/66 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/52 ,  C07K2317/54 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include antagonist antibodies that bind PD-1. Such antibodies can be used in methods to treat, for example, cancer.

公开(公告)号：US20240052064A1

公开(公告)日：2024-02-15

申请号：US17798983

申请日：2021-02-11

Applicant: BRISTOL-MYERS SQUIBB COMPANY

Inventor： Kofi MENSAH ,  Robert PLENGE ,  Sophie ROY ,  Dennis ZALLER ,  Jennifer DOVEY ,  Steven SAENZ ,  Jill HENAULT ,  Camille DOYKAN ,  Jenna CALVINO ,  Xi JIN ,  Joseph PAQUETTE

IPC: C07K16/46 ,  A61P37/02

CPC classification number: C07K16/468 ,  A61P37/02 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/52 ,  C07K2317/565

Abstract: The present invention relates to the treatment or management of autoimmune disorders, such as autoimmune disorders caused by autoreactive B lineage cells, e.g. anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).

公开(公告)号：US20240043568A1

公开(公告)日：2024-02-08

申请号：US18265114

申请日：2021-12-02

Applicant: KEYMED BIOSCIENCES CO.,LTD

Inventor： Bo CHEN ,  Gang XU ,  Qin SONG

IPC: C07K16/46 ,  C12N15/63 ,  A61P35/00 ,  G01N33/574

CPC classification number: C07K16/468 ,  C12N15/63 ,  A61P35/00 ,  G01N33/574 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/52

Abstract: The present disclosure relates to the development of a new tumor engager therapeutic drug and the use thereof. The therapeutic drug contains a bispecific antibody that binds to GPC3 and CD3, wherein the bispecific antibody contains a first binding domain that binds to GPC3 on the surface of a target cell and a second binding domain that binds to CD3 on the surface of a T cell. The bispecific antibody can inhibit tumor growth at a very low dose and effectively inhibit the growth of a transplanted tumor in an immune reconstitution mouse. A toxicological study conducted in cynomolgus monkeys also shows that animals have good tolerance to the bispecific antibody, and the efficacy and safety of the bispecific antibody are superior to those of similar antibodies.

公开(公告)号：US20240034770A1

公开(公告)日：2024-02-01

申请号：US18201911

申请日：2023-05-25

Applicant: Cue Biopharma, Inc.

Inventor： Anish Suri ,  Saso Cemerski ,  Chee Meng Low ,  Raymond J. Moniz ,  Gurpanna Saggu

IPC: C07K14/74 ,  C07K14/55 ,  C07K16/28 ,  C07K14/005

CPC classification number: C07K14/70539 ,  C07K14/55 ,  C07K16/2803 ,  C07K14/005 ,  C07K2317/622 ,  C07K2317/52 ,  C12N2710/16134 ,  C07K2319/33 ,  A61K39/00

Abstract: The present disclosure provides T-cell modulatory multimeric polypeptides (TMMPs) that comprise an immunomodulatory polypeptide, class I HLA polypeptides (a class I HLA heavy chain polypeptide and a β2 microglobulin polypeptide), a peptide that presents an epitope to a T-cell receptor, and a tumor-targeting polypeptide. A TMMP is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.

公开(公告)号：US20240033292A1

公开(公告)日：2024-02-01

申请号：US18321517

申请日：2023-05-22

Applicant: AUTOLUS LIMITED

Inventor： Martin Pulé ,  Khai Kong ,  Shaun Cordoba

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86 ,  C12N9/16

CPC classification number: A61K35/17 ,  A61K39/0011 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70589 ,  C07K16/2803 ,  C12N5/0638 ,  C12N5/0646 ,  C07K14/70503 ,  C12N5/0636 ,  C12N15/86 ,  C12N5/0637 ,  C12N9/16 ,  C12Y301/03048 ,  A61K2039/5158 ,  C12N2510/00 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2319/01 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2740/10043 ,  C12N2740/15043 ,  A61K38/00

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a transmembrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, wherein the spacer of the first CAR is different to the spacer of the second CAR and wherein one of the first or second CARs is an activating CAR comprising an activating endodomain and the other CAR is an inhibitory CAR comprising a ligation-off inhibitory endodomain.

公开(公告)号：US20240033289A1

公开(公告)日：2024-02-01

申请号：US18158310

申请日：2023-01-23

Applicant: AUTOLUS LIMITED

Inventor： Martin Pulé ,  Khai Kong ,  Shaun Cordoba

IPC: A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K14/705 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86 ,  C12N9/16

CPC classification number: A61K35/17 ,  A61K38/00 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70589 ,  C07K16/2803 ,  C12N5/0638 ,  C12N5/0646 ,  C07K14/70503 ,  C12N5/0636 ,  C12N15/86 ,  C12N5/0637 ,  C12N9/16 ,  C12Y301/03048 ,  A61K2039/5158 ,  C12N2510/00 ,  C07K2317/52 ,  C07K2317/622 ,  C07K2319/01 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2740/10043 ,  C12N2740/15043 ,  A61K39/0011

Abstract: The present invention provides a cell which co-expresses a first chimeric antigen receptor (CAR) and second CAR at the cell surface, each CAR comprising: (i) an antigen-binding domain; (ii) a spacer (iii) a trans-membrane domain; and (iv) an endodomain wherein the antigen binding domains of the first and second CARs bind to different antigens, and wherein each of the first and second CARs is an activating CAR comprising an activating endodomain.

公开(公告)号：US20240026035A1

公开(公告)日：2024-01-25

申请号：US18256917

申请日：2021-12-13

Applicant: VANDERBILT UNIVERSITY

Inventor： Scott A. SMITH

IPC: C07K16/44 ,  G01N33/53 ,  A61P37/08 ,  G01N33/68 ,  A61K39/35

CPC classification number: C07K16/44 ,  G01N33/5308 ,  A61P37/08 ,  G01N33/6854 ,  A61K39/35 ,  G01N2800/24 ,  G01N2400/00 ,  C07K2317/52 ,  C07K2317/72 ,  C07K2317/41 ,  C07K2317/94 ,  A61K2039/577

Abstract: The present disclosure is directed to human IgE antibodies and fragments thereof binding to galactose-α-1, 3-galactose, a known red meat allergen, and methods for use thereof.

公开(公告)号：US11879016B2

公开(公告)日：2024-01-23

申请号：US17196670

申请日：2021-03-09

Applicant: AUTOLUS LIMITED

Inventor： Martin Pulé ,  John Anderson ,  Simon Thomas

IPC: C07K16/30 ,  C07K14/725 ,  C07K14/705 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  C12N15/85 ,  A61K39/00

CPC classification number: C07K16/3084 ,  A61K35/17 ,  A61K38/179 ,  A61K38/1774 ,  A61K39/39558 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C12N15/85 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/20 ,  C07K2319/30 ,  C12N2510/00

Abstract: Provision of a chimeric antigen receptor (CAR) comprising a disialoganglioside (GD2)-binding domain which comprises •a) a heavy chain variable region (VH) having complementarity determining regions (CDRs) with the following sequences: •b) a light chain variable region (VL) having CDRs with the following sequences: T cells expressing such a CAR are useful in the treatment of some cancers.